Project Navigator
Let's try to finance it!
A new, user friendly way, to get information about current clinical trials available to prostate cancer patients.
Tags
177Lu-PSMA-617 225Ac abiraterone abiraterone acetate ADC ADT ai in healthcare antibody-drug conjugate apalutamide ATM B7-H3 bispecific antibody bone metastases bone metastasis BRCA BRCA2 cancer immunotherapy CAR-T CD3 clinical trial crispr darolutamide docetaxel drug repurposing enzalutamide EZH2 inhibitor HRR immunotherapy mcrpc mHSPC mRNA NEPC neuroendocrine prostate cancer oncolytic virus PARP1 PARP inhibitor Pluvicto prostate cancer protac PSMA radioligand therapy radiopharmaceuticals real-world data STEAP1 T-cell therapy
Latest Posts
- Newsletter 37/2026 September 13, 2026
- Reading the DNA Fingerprints of Prostate Cancer September 12, 2026
- Phase 1/2 Trial Results for Tinengotinib (TT-00420) in mCRPC September 12, 2026
- STAMINA: Supervised Exercise and Dietary Advice Cut ADT-Related Decline in Prostate Cancer September 8, 2026
New Study Targets Tumor Cell Clusters to Combat Metastasis
/in Not PCa related/by MaxPhase 1 Trial: Pocenbrodib, A New (AI Based) Approach for mCRPC
/in Clinical Trial, Metastatic, Phase 1/by MaxPhase 1/2 Study: Evofosfamide With Immune Checkpoint Inhibitors for Advanced Cancers
/in Clinical Trial, Metastatic, Phase 1/by MaxAAA817 (225Ac-PSMA-617) Phase2/3 Trial Will Start Recruiting Soon
/in Clinical Trial, Metastatic, Phase 2/by MaxIPH4502 Phase 1 Clinical Trial for Solid Tumors Expressing Nectin-4
/in Clinical Trial, Metastatic, Phase 1/by MaxModified Virus Shows Promise in Shrinking Tumors and Halting Cancer Growth
/in Not PCa related/by MaxGoogle’s AI-Driven Breakthrough: The Future of Drug Discovery
/in Artificial Intelligence/by MaxWe can’t always win: LAVA-1207 Development Discontinued, Not Related to Safety Issues
/in Clinical Trial, Metastatic, Phase 1/by Max